Wall Street brokerages expect Monsanto (NYSE:MON) to post earnings of $2.19 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Monsanto’s earnings. The highest EPS estimate is $2.56 and the lowest is $2.05. Monsanto reported earnings per share of $1.93 during the same quarter last year, which would indicate a positive year over year growth rate of 13.5%. The firm is scheduled to report its next earnings report on Wednesday, June 27th.
On average, analysts expect that Monsanto will report full-year earnings of $5.70 per share for the current fiscal year, with EPS estimates ranging from $5.50 to $6.00. For the next financial year, analysts forecast that the business will report earnings of $6.30 per share, with EPS estimates ranging from $5.50 to $7.00. Zacks’ EPS calculations are an average based on a survey of analysts that cover Monsanto.
Top 5 Performing Stocks To Buy For 2021: BlackBerry Limited(BBRY)
Product and business developments that have influenced the general development of the Company's business over the last three fiscal years are as follows: Fiscal 2016: Significant Acquisition * On October 30, 2015, the Company, through its wholly-owned subsidiary, BlackBerry Corporation, acquired all of the issued and outstanding shares of Good Technology Corporation ("Good"), a provider of secure mobility solutions, including secure applications and containerization that protects end user privacy. The aggregate consideration paid by the Company was approximately $417 million and consisted of (i) the payment of approximately $328.4 million in cash to existing shareholders of Good, and (ii) the payment of approximately $88.6 million to existing debtholders of Good. The Company financed the acquisition from its own cash and investment balances. Advisors' Opinion:
- [By Shane Hupp]
BlackBerry (TSE:BB) (NASDAQ:BBRY)‘s stock had its “in-line” rating reiterated by analysts at Imperial Capital in a report issued on Wednesday.
Top 5 Performing Stocks To Buy For 2021: 8x8 Inc(EGHT)
8x8, Inc. develops and markets telecommunications services for Internet protocol (IP), telephony, and video applications. The company offers 8x8 Virtual Office Business Telephone Service, an alternative to traditional private branch exchange systems that offers automated attendants to assist callers; extension-to-extension dialing services; direct inward dial; conference bridge, 3-way calling, music on hold, call park/pick-up, call transfer, hunt groups, and do not disturb services; voice mail, including email alerts and direct transfer to mailbox; call waiting/caller-ID; distinctive tone ringing; and optional receptionist console applications. Its products also include 8x8 Complete Contact Center, an integrated hosted call center solution that consists of skill-based routing, multi-media management, real time monitoring and reporting, voice recording and logging, historical reporting, interactive voice response, CRM integration, and contact and case management tools; 8x8 IP Telephones; 8x8 Virtual Meeting, a video Web conferencing service; and 8x8 Managed Hosting and Cloud-Based Computing Solutions. In addition, the company offers 8x8 Virtual Office Pro Unified Communications that allows subscribers to manage business communications functions online and delivers various tools, such as Microsoft Outlook contacts and corporate directory integration; virtual meeting; Virtual Office Mobile extension; fax; call recording; presence management; and a view of voicemails, recordings, FAX messages, calls, and chat history. The company markets its services under 8x8 brand to end users through direct sales force, Web site, and third party resellers primarily in the United States. As of June 30, 2011, it had approximately 25,000 business customers. 8x8, Inc. was founded in 1987 and is headquartered in Sunnyvale, California.
Advisors' Opinion:- [By Max Byerly]
Equities research analysts at William Blair started coverage on shares of 8X8 (NASDAQ:EGHT) in a research report issued to clients and investors on Wednesday, The Fly reports. The firm set a “buy” rating on the technology company’s stock.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on 8X8 (EGHT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Anders Bylund]
RingCentral (NYSE:RNG) led the way with a 26.3% surge, followed by 8x8 (NYSE:EGHT) at 13.8% and Vonage Holdings (NYSE:VG) scoring a 10.7% gain. All of these one-month returns crushed the broader market, as the S&P 500 benchmark notched just a 3% gain last month.
Top 5 Performing Stocks To Buy For 2021: Orexigen Therapeutics, Inc.(OREX)
Orexigen Therapeutics, Inc., incorporated on September 12, 2002, is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.
The Company competes with Genentech, Inc., Eisai Inc., GlaxoSmithKline, Arena Pharmaceuticals, Inc., Vivus, Inc., Novo Nordisk, Johnson & Johnson, Apollo Endosurgery, Boston Scientific, Covidien Ltd., EnteroMedics, Inc., GI Dynamics, Inc. and Medtronic, Inc.
Advisors' Opinion:- [By Stephan Byrd]
Media headlines about Orexigen Therapeutics (NASDAQ:OREX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Orexigen Therapeutics earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.6752029162772 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
- [By Paul Ausick]
Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 12% Tuesday and posted a new 52-week low of $0.29 after closing Monday at $0.33. The stock’s 52-week high is $4.46. Volume was around 5.9 million, about 8 times the daily average. The company filed Monday for Chapter 11 bankruptcy.
Top 5 Performing Stocks To Buy For 2021: Sunoco Logistics Partners LP(SXL)
Sunoco Logistics Partners L.P. transports, terminals, and stores crude oil, refined products, and natural gas liquids (NGLs). It operates through four segments: Crude Oil Pipelines, Crude Oil Acquisition and Marketing, Terminal Facilities, and Products Pipelines. The Crude Oil Pipelines segment transports crude oil primarily in Oklahoma and Texas. It contains approximately 5,300 miles of crude oil trunk pipelines, as well as approximately 500 miles of crude oil gathering lines. The Crude Oil Acquisition and Marketing segment gathers, purchases, markets, and sells crude oil principally in the mid-continent United States. It utilizes the company's proprietary fleet of approximately 335 crude oil transport trucks, and approximately 135 crude oil truck unloading facilities, as well as third-party assets. The Terminal Facilities segment operates crude oil, refined products, and NGL terminals, as well as markets refined products and NGLs. The segment operates with an aggregate storage capacity of approximately 48 million barrels, including the 25 million barrel Nederland, Texas crude oil, and NGL terminal; the 6 million barrel Eagle Point, New Jersey refined products and crude oil terminal; the 3 million barrel Marcus Hook, Pennsylvania refined products and NGL facility; 39 active refined products marketing terminals located in the northeast, midwest, and southwest United States; and refinery terminals located in the northeast United States. The Products Pipelines segment transports refined products and NGLs in the northeast, midwest, and southwest United States. Its products pipeline consists of approximately 2,400 miles of refined products and NGL pipelines, and joint venture interests in 4 products pipelines in the United States. Sunoco Partners LLC serves as the general partner of the company. The company was founded in 2001 and is based in Philadelphia, Pennsylvania.
ILLEGAL ACTIVITY NOTICE: “Southern Cross Media Group Ltd (SXL) Declares $0.04 Interim Dividend” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/4173757/southern-cross-media-group-ltd-sxl-declares-0-04-interim-dividend.html. NeoGenomics, Inc., through its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for certain stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. February was a great month for genetic testing stocks. Shares of Invitae (NYSE:NVTA) paced the pack with a monthly gain of 42.9%, according to data provided by S&P Global Market Intelligence. That was followed by NeoGenomics (NASDAQ:NEO) and Myriad Genetics (NASDAQ:MYGN), which rose 17.9% and 10.1%, respectively. Investors waited for years, hoping that genetic-testing companies would live up to their awesome potential to improve medicine and usher in the first wave of personalized healthcare. That patience finally began paying off in 2018 as multiple companies, including Genomic Health (NASDAQ:GHDX) and NeoGenomics (NASDAQ:NEO), turned profitable, while others held highly anticipated initial public offerings. NEO (CURRENCY:NEO) traded up 2.4% against the U.S. dollar during the twenty-four hour period ending at 20:00 PM Eastern on February 2nd. One NEO coin can currently be purchased for $7.19 or 0.00205255 BTC on popular cryptocurrency exchanges including Cryptopia, Gate.io, Bittrex and Ovis. NEO has a market cap of $467.28 million and $108.59 million worth of NEO was traded on exchanges in the last 24 hours. During the last week, NEO has traded down 3.9% against the U.S. dollar. NEO (CURRENCY:NEO) traded up 3.5% against the dollar during the 1-day period ending at 16:00 PM Eastern on October 8th. NEO has a market capitalization of $1.21 billion and $161.27 million worth of NEO was traded on exchanges in the last day. One NEO coin can currently be purchased for approximately $18.64 or 0.00280368 BTC on major cryptocurrency exchanges including LBank, ZB.COM, Gate.io and Allcoin. In the last seven days, NEO has traded up 0.6% against the dollar. Top 5 Performing Stocks To Buy For 2021: NeoGenomics, Inc.(NEO)
No comments:
Post a Comment